Microfluidic technology offers a reliable, cost-effective, accurate, and sensitive way to move and/or analyze liquids, including processing of the liquids such as in mixing or chemical reactions. The Sievers Eclipse Bacterial Endotoxin Test (BET) Platform uses microfluidic automation to optimize BET testing without jeopardizing consistency or compliance. Not only is microfluidic automation the simplest form of BET testing available to the market today, but it enables a faster setup time and reduces opportunities for error in your BET testing.
Current manual endotoxin testing methods require hundreds of pipetting steps, are difficult to ensure consistency, and are prone to mistakes and costly retests. This challenging and inefficient process can take upwards of 60 minutes to manually start an assay.
In comparison, the Sievers Eclipse centripetal microfluidic technology is achieved with a compact microplate that is analyzed using an incubating benchtop spectrophotometer that is similar in size and function to absorbance microplate readers. Through the manipulation of small reaction volumes within narrow channels, the Eclipse uses a centripetal microfluidic plate to direct and mix fluids to automate endotoxin assays without using robotics.
On top of reducing the amount of time needed to complete an assay, the Sievers Eclipse microplate can also reduce the cost and consumption of reagents and samples. The Sievers Eclipse only requires 1 mL of LAL reagent for 21 samples. That is equivalent to 63 samples run on the Eclipse from just one vial of lysate. In addition to being efficient and cost-effective, the Sievers Eclipse uses the same reagents as traditional 96-well plate kinetic chromogenic methods.
Learn more about the innovative technology behind the consistent, compliant, and conscious Sievers Eclipse BET Platform here.